tirzepatide glp 1 agonist GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 π GLP-1 Spotlight: Semaglutide vs
Description
It enhances insulin secretion from pancreatic -cells, and decreases glucagon release from pancreatic -cells [16]
Plummer MP, Jones KL, Annink CE, et al
Conclusion The emergence of lower-cost GLP-1 therapies could mark a major turning point in diabetes management
Dietary restrictions combined with appetite suppression could push caloric intake dangerously low
Weigh the risks of side effects Despite reports of some serious side effects, Levy says these medications have a pretty solid safety record
Even though the oral dose is higher, only a tiny fraction actually enters the bloodstream
